arginine salt of D(-)-3-hydroxybutanoic acid | 132796-01-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: arginine salt of D(-)-3-hydroxybutanoic acid
• 英文别名: (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid;3-hydroxybutanoic acid
• CAS: 132796-01-1
• 化学式: C₄H₈O₃*C₆H₁₄N₄O₂
• 分子量: 278.308
• InChiKey: PWMKRDMOSNBALO-WCCKRBBISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  185
• 氢给体数：
  6
• 氢受体数：
  7

文献信息

• Administration of berberine metabolites
  申请人：Keto Patent Group, Inc.

  公开号：US10278961B2

  公开（公告）日：2019-05-07

  In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.

  在各种实施方案中，小檗碱代谢物，如二氢小檗碱和/或四氢小檗碱，可用于控制血糖水平、提高酮体水平（如血液中酮体浓度）和/或用于人类的治疗目的。给药有效量的小檗碱代谢物，如二氢小檗碱，可降低空腹血糖水平，改善葡萄糖耐量，和/或改善血酮反应。在某些实施方案中，小檗碱代谢物可与一种或多种其他化合物一起施用。
• Compositions and methods for producing elevated and sustained ketosis
  申请人：University of South Florida

  公开号：US10646462B2

  公开（公告）日：2020-05-12

  Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

  β-羟基丁酸盐矿物盐与中链脂肪酸或其酯类（如中链甘油三酯）相结合，用于诱导酮病，在限制饮食或不限制饮食的情况下，使血酮水平达到（2-7 毫摩尔/升）。这种组合能在短时间内显著改善与胰岛素抵抗、糖尿病、体重减轻和体能表现有关的代谢生物标志物。此外，使用这些补充剂来达到酮病的目的，可显著提高血酮水平，降低血糖水平。使用这些物质不会对血脂产生不利影响。通过快速启动酮病和加快酮适应的速度，本发明可用于避免开始生酮饮食的人通常会出现的葡萄糖戒断症状，并最大限度地减少饮食限制期间瘦体重的损失。
• Metabolic therapy for wound healing
  申请人：University of South Florida

  公开号：US10864184B1

  公开（公告）日：2020-12-15

  Ketone supplementation, such as through use of precursors of beta-hydroxybutyrate (BHB) and acetoacetate (AcAc), increased blood levels of ketone bodies, increases blood flow and wound closure in ischemic young and aged fisher rats significantly earlier compared to standard diet in aged rats. In vitro experiments with ketone bodies demonstrate decreased mitochondrial and cytosolic ROS in young and aged primary human dermal fibroblasts (PHDF). Ketone bodies increased migration in young and aged PHDFs.

  与标准饮食的老年大鼠相比，补充酮体（如使用 beta-羟基丁酸（BHB）和乙酰乙酸（AcAc）的前体）可提高血液中的酮体水平，增加缺血的年轻和老年渔鼠的血流量，并显著提前伤口闭合。酮体的体外实验表明，年轻和衰老的原发性人真皮成纤维细胞（PHDF）线粒体和细胞膜 ROS 减少。酮体增加了年轻和衰老的原发性人真皮成纤维细胞的迁移。
• Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
  申请人：Keto Patent Group, Inc.

  公开号：US11173138B2

  公开（公告）日：2021-11-16

  In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. Other compounds may include short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof.

  在各种实施方案中，β-羟基丁酸盐、相关化合物和/或一种或多种其他化合物可被施用于个体，以减轻体重、维持体重、提高血酮水平、维持血酮水平、降低血糖水平、维持血糖水平、改善能量、注意力、情绪、认知功能或辅助治疗神经或炎症性疾病和/或其组合。 其他化合物可包括短链脂肪酸、短链甘油三酯、中链脂肪酸、中链甘油三酯、长链脂肪酸、长链甘油三酯、小檗碱、小檗碱的代谢物（如二氢小檗碱）和/或其组合。
• COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS
  申请人：University Of South Florida

  公开号：EP2976073A1

  公开（公告）日：2016-01-27